Adhesion formation is a major post-surgical complication. The term "adhesion" is used to describe abnormal attachments between tissues or organs or between tissues and implants (e.g. prosthetic devices) formed after an inflammatory stimulus (i.e. surgery), that produces considerable pain and discomfort. The incidence of post-surgery adhesion approaches 100%, with a clinically significant complication rate of 3-8%, depending on surgery type i,ii. Adhesion formation after open-heart surgery, for example, is a well-documented, significant complication during secondary procedures which account for 15% to 20% of the approximately 450,000 surgeries performed annually in the US and the 350,000 surgeries performed annually throughout the EU.
The aim of the ADHESION Project is to strengthen the anti-adhesion and anti-bacterial characteristics of a NOVAGENIT® proprietary product (DAC®), by tuning and validating a new more competitive solution targeted to the orthopaedic and cardiovascular surgery. NOVAGENIT® will take the opportunity to expand its own business in the anti-adhesion market by taking advantage of the intrinsic barrier effect of the DAC® hydrogel.
Coordinator of the project: NOVAGENIT Srl – Italy
Funding programme: H2020-SMEINST-1-2014
Project start: 1 May 2015
End date for the project: 30 October 2015